TRIO-TECH INTERNATIONAL (TRT) Fundamental Analysis & Valuation

NYSEARCA:TRT • US8967122057

5.97 USD
+0.22 (+3.83%)
Last: Mar 10, 2026, 03:19 PM

This TRT fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

3

TRT gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 115 industry peers in the Semiconductors & Semiconductor Equipment industry. The financial health of TRT is average, but there are quite some concerns on its profitability. TRT has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

3

1. TRT Profitability Analysis

1.1 Basic Checks

  • In the past year TRT has reported negative net income.
  • TRT had a positive operating cash flow in the past year.
  • In multiple years TRT reported negative net income over the last 5 years.
  • In the past 5 years TRT always reported a positive cash flow from operatings.
TRT Yearly Net Income VS EBIT VS OCF VS FCFTRT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 2M 4M 6M 8M

1.2 Ratios

  • With a Return On Assets value of -0.24%, TRT perfoms like the industry average, outperforming 47.83% of the companies in the same industry.
  • TRT has a Return On Equity (-0.33%) which is comparable to the rest of the industry.
  • Looking at the Return On Invested Capital, with a value of 0.49%, TRT is in line with its industry, outperforming 48.70% of the companies in the same industry.
  • Measured over the past 3 years, the Average Return On Invested Capital for TRT is significantly below the industry average of 10.52%.
Industry RankSector Rank
ROA -0.24%
ROE -0.33%
ROIC 0.49%
ROA(3y)2.01%
ROA(5y)2%
ROE(3y)2.82%
ROE(5y)2.96%
ROIC(3y)2.81%
ROIC(5y)N/A
TRT Yearly ROA, ROE, ROICTRT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 2 -2 4 6 8

1.3 Margins

  • TRT has a Operating Margin (0.43%) which is comparable to the rest of the industry.
  • TRT's Operating Margin has declined in the last couple of years.
  • TRT's Gross Margin of 19.68% is on the low side compared to the rest of the industry. TRT is outperformed by 79.13% of its industry peers.
  • TRT's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 0.43%
PM (TTM) N/A
GM 19.68%
OM growth 3Y-57.25%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.98%
GM growth 5Y3.52%
TRT Yearly Profit, Operating, Gross MarginsTRT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5 10 15 20 25

5

2. TRT Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so TRT is destroying value.
  • Compared to 1 year ago, TRT has more shares outstanding
  • The number of shares outstanding for TRT has been increased compared to 5 years ago.
  • Compared to 1 year ago, TRT has an improved debt to assets ratio.
TRT Yearly Shares OutstandingTRT Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M
TRT Yearly Total Debt VS Total AssetsTRT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M

2.2 Solvency

  • An Altman-Z score of 4.50 indicates that TRT is not in any danger for bankruptcy at the moment.
  • The Altman-Z score of TRT (4.50) is comparable to the rest of the industry.
  • The Debt to FCF ratio of TRT is 7.26, which is on the high side as it means it would take TRT, 7.26 years of fcf income to pay off all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 7.26, TRT is in line with its industry, outperforming 50.43% of the companies in the same industry.
  • TRT has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
  • TRT's Debt to Equity ratio of 0.02 is fine compared to the rest of the industry. TRT outperforms 66.09% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF 7.26
Altman-Z 4.5
ROIC/WACC0.04
WACC11.34%
TRT Yearly LT Debt VS Equity VS FCFTRT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10M 20M 30M

2.3 Liquidity

  • TRT has a Current Ratio of 2.96. This indicates that TRT is financially healthy and has no problem in meeting its short term obligations.
  • TRT's Current ratio of 2.96 is in line compared to the rest of the industry. TRT outperforms 53.04% of its industry peers.
  • A Quick Ratio of 2.72 indicates that TRT has no problem at all paying its short term obligations.
  • TRT has a Quick ratio (2.72) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.96
Quick Ratio 2.72
TRT Yearly Current Assets VS Current LiabilitesTRT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M

2

3. TRT Growth Analysis

3.1 Past

  • TRT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -130.03%.
  • The Revenue has grown by 27.63% in the past year. This is a very strong growth!
  • Measured over the past years, TRT shows a small growth in Revenue. The Revenue has been growing by 1.14% on average per year.
EPS 1Y (TTM)-130.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-85%
Revenue 1Y (TTM)27.63%
Revenue growth 3Y-6.11%
Revenue growth 5Y1.14%
Sales Q2Q%81.56%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
TRT Yearly Revenue VS EstimatesTRT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M

1

4. TRT Valuation Analysis

4.1 Price/Earnings Ratio

  • TRT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TRT Price Earnings VS Forward Price EarningsTRT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, TRT is valued cheaply inside the industry as 88.70% of the companies are valued more expensively.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of TRT is on the same level as its industry peers.
Industry RankSector Rank
P/FCF 381.3
EV/EBITDA 12.13
TRT Per share dataTRT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3 4 5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

0

5. TRT Dividend Analysis

5.1 Amount

  • TRT does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

TRT Fundamentals: All Metrics, Ratios and Statistics

TRIO-TECH INTERNATIONAL

NYSEARCA:TRT (3/10/2026, 3:19:22 PM)

5.97

+0.22 (+3.83%)

Chartmill FA Rating
GICS IndustryGroupSemiconductors & Semiconductor Equipment
GICS IndustrySemiconductors & Semiconductor Equipment
Earnings (Last)02-13
Earnings (Next)05-11
Inst Owners22.53%
Inst Owner Change-1.65%
Ins Owners27.02%
Ins Owner Change5.46%
Market Cap52.24M
Revenue(TTM)49.22M
Net Income(TTM)-109.00K
Analysts0
Price TargetN/A
Short Float %0.23%
Short Ratio0.14
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.06
P/FCF 381.3
P/OCF 44.12
P/B 1.56
P/tB 1.56
EV/EBITDA 12.13
EPS(TTM)-0.02
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0.02
FCFY0.26%
OCF(TTM)0.14
OCFY2.27%
SpS5.62
BVpS3.83
TBVpS3.83
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -0.24%
ROE -0.33%
ROCE 0.62%
ROIC 0.49%
ROICexc 0.93%
ROICexgc 0.93%
OM 0.43%
PM (TTM) N/A
GM 19.68%
FCFM 0.28%
ROA(3y)2.01%
ROA(5y)2%
ROE(3y)2.82%
ROE(5y)2.96%
ROIC(3y)2.81%
ROIC(5y)N/A
ROICexc(3y)5.18%
ROICexc(5y)N/A
ROICexgc(3y)5.18%
ROICexgc(5y)N/A
ROCE(3y)3.55%
ROCE(5y)N/A
ROICexgc growth 3Y-59.08%
ROICexgc growth 5YN/A
ROICexc growth 3Y-59.08%
ROICexc growth 5YN/A
OM growth 3Y-57.25%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.98%
GM growth 5Y3.52%
F-Score4
Asset Turnover1.08
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF 7.26
Debt/EBITDA 0.28
Cap/Depr 45.68%
Cap/Sales 2.13%
Interest Coverage 3.37
Cash Conversion 47.28%
Profit Quality N/A
Current Ratio 2.96
Quick Ratio 2.72
Altman-Z 4.5
F-Score4
WACC11.34%
ROIC/WACC0.04
Cap/Depr(3y)45.5%
Cap/Depr(5y)44.1%
Cap/Sales(3y)4.78%
Cap/Sales(5y)4.22%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-130.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-85%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)27.63%
Revenue growth 3Y-6.11%
Revenue growth 5Y1.14%
Sales Q2Q%81.56%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-55.27%
EBIT growth 3Y-59.86%
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-97.23%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-78.88%
OCF growth 3Y-44.07%
OCF growth 5Y-34.21%

TRIO-TECH INTERNATIONAL / TRT FAQ

Can you provide the ChartMill fundamental rating for TRIO-TECH INTERNATIONAL?

ChartMill assigns a fundamental rating of 3 / 10 to TRT.


Can you provide the valuation status for TRIO-TECH INTERNATIONAL?

ChartMill assigns a valuation rating of 1 / 10 to TRIO-TECH INTERNATIONAL (TRT). This can be considered as Overvalued.


Can you provide the profitability details for TRIO-TECH INTERNATIONAL?

TRIO-TECH INTERNATIONAL (TRT) has a profitability rating of 3 / 10.


What is the financial health of TRIO-TECH INTERNATIONAL (TRT) stock?

The financial health rating of TRIO-TECH INTERNATIONAL (TRT) is 5 / 10.